BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20497747)

  • 1. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.
    Jones MP; Nicholl D; Trakas K
    Int J Clin Pharmacol Ther; 2010 Jun; 48(6):383-99. PubMed ID: 20497747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
    Owen RT
    Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
    Melnik T; Soares BG; Puga ME; Atallah AN
    Sao Paulo Med J; 2010 May; 128(3):141-66. PubMed ID: 20963366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone extended-release for the treatment of schizophrenia.
    Marino J; Caballero J
    Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
    Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M
    J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
    Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
    BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
    Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
    Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paliperidone extended release.
    Yang LP; Plosker GL
    CNS Drugs; 2007; 21(5):417-25; discussion 426-7. PubMed ID: 17447829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone for treatment of schizophrenia.
    Nussbaum AM; Stroup TS
    Schizophr Bull; 2008 May; 34(3):419-22. PubMed ID: 18375569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone for schizophrenia.
    Dolder C; Nelson M; Deyo Z
    Am J Health Syst Pharm; 2008 Mar; 65(5):403-13. PubMed ID: 18281731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paliperidone for schizophrenia.
    Nussbaum A; Stroup TS
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006369. PubMed ID: 18425951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone extended-release: does it have a place in antipsychotic therapy?
    Gahr M; Kölle MA; Schönfeldt-Lecuona C; Lepping P; Freudenmann RW
    Drug Des Devel Ther; 2011 Mar; 5():125-46. PubMed ID: 21448450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.
    Harrington CA; English C
    Int Clin Psychopharmacol; 2010 Nov; 25(6):334-41. PubMed ID: 20706126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
    Pani L; Marchese G
    Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.